Melanoma Cancer Contract Phase 1 was Aethlon Medical’s largest revenue line in fiscal 2019, bringing in $149.63K of $229.63K (65%).
| Deferred Revenue Arrangement Type | FY 2019 |
|---|---|
| Melanoma Cancer Contract Phase 1 | $149.63K |
| Breast Cancer Grant | $80.00K |
| Total | $229.63K |
Aethlon Medical brought in $229.63K from its two revenue lines in fiscal 2019, the year ended March 31, 2019. Melanoma Cancer Contract Phase 1 was the largest at $149.63K (65.2%), ahead of Breast Cancer Grant at $80.00K (34.8%).
Aethlon Medical (AEMD) reports its revenue by deferred revenue arrangement type. In fiscal 2019, Melanoma Cancer Contract Phase 1 was its largest revenue line, bringing in $149.63K (65.2% of the total), followed by Breast Cancer Grant at $80.00K (34.8%).
Melanoma Cancer Contract Phase 1 was Aethlon Medical's largest revenue line in fiscal 2019, bringing in $149.63K, or 65.2% of the $229.63K total across its two revenue lines.
Every figure comes from Aethlon Medical's annual financial filings, as reported. Each line keeps the name Aethlon Medical gives it, and years follow its fiscal calendar.
Aethlon Medical's revenue by deferred revenue arrangement type goes back to fiscal 2019, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.